Europe’s Tech Services Market Slows in Q3, Despite Strong AI-Driven Cloud Demand: ISG Index™
14.10.2025 10:00:00 CEST | Business Wire | Press Release
Europe’s market for technology services and software slowed in the third quarter despite continuing strong demand for AI, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.
The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both managed services and cloud-based as-a-service) rose 5 percent, to US $9.7 billion. Although the market has grown for seven consecutive quarters, averaging 14 percent quarterly growth during that span, the rate of growth in the third quarter was the lowest since the second quarter last year.
“The market in Europe continues to be buoyed by strong, double-digit growth in cloud services as companies race to realize their AI ambitions,” said Steve Hall, president, ISG EMEA and the firm’s chief AI officer. “That growth, however, masks an underlying weakness in managed services. Macro instability, tariff pressure and political risk are slowing deal approvals. We’re seeing deals scoped but not closed. Clients are active, but cautious—and prioritizing only what clearly ties to outcomes.”
Third-Quarter Results by Segment
ACV for the as-a-service (XaaS) segment soared 41 percent year on year, to a record US $5.9 billion. It was the sixth straight quarter XaaS has grown by double digits, averaging 33 percent quarterly growth in that span. Growth accelerated from the second quarter, up 840 basis points in Q3.
Within this segment, infrastructure-as-a-service (IaaS) climbed 50 percent year on year, to a record US $4.5 billion. Software-as-a-service (SaaS) grew 17 percent, to US $1.3 billion.
Managed services ACV in the third quarter slumped 25 percent, to US $3.8 billion. A total of 247 managed services contracts were awarded in the quarter, down 22 percent from the prior year but up 5 percent from Q2. Among them were two mega deals (ACV of US $100 million or more), compared with six signed in the third quarter last year. The volume of smaller deals under US $10 million declined 38 percent year on year, as enterprises limited discretionary projects.
Within managed services, IT outsourcing (ITO) slid 28 percent, to US $2.7 billion. Business process outsourcing (BPO) also fell, down 27 percent, to US $815 million. Engineering, research and development (ER&D) was the lone bright spot, up 49 percent, to US $309 million, fueled by demand for AI-related software engineering.
Among the region’s major sectors, managed services ACV was higher in manufacturing (up 30 percent) and energy (up 9 percent), but declined 18 percent in banking, financial services and insurance (BFSI), Europe’s largest industry for sourcing.
Geographic Performance
Among EMEA’s largest managed services markets, the U.K. and Ireland declined 7 percent year on year, to US $999 million, while the DACH region fell 60 percent, to US $839 million, and France slumped 26 percent, to US $412 million. The Nordics, meanwhile, soared 106 percent, to US $595 million, and Southern Europe advanced 29 percent, to US $322 million.
Nine-Month Results
For the first nine months, combined market ACV rose 13.5 percent, to US $28.1 billion. Managed services, at US $12.0 billion, was down 8 percent, while XaaS, at US $16.1 billion, rose 37 percent versus the same period last year. A total of 760 managed services contracts were awarded year to date, down 15 percent from last year, including eight mega-deals, compared with 12 in the prior year. The total ACV of the mega-deals declined 40 percent year on year.
Within managed services, ITO was down 11 percent, to US $8.8 billion, while BPO declined 20 percent, to US $2.0 billion. ER&D services soared 83 percent, to US $1.2 billion of ACV.
On the cloud side, the IaaS market grew 43 percent, to US $12.0 billion, while the SaaS market rose 22 percent, to US $4.1 billion.
2025 Global Forecast
For the full year, ISG is maintaining its forecast of 1.3 percent revenue growth for managed services, with strong growth in the Americas offset by weakness in Europe and Asia Pacific. At the same time, ISG is raising its previous growth forecast for cloud-based XaaS by 400 basis points, to 25 percent, led by continuing strong, AI-driven demand for IaaS.
Hall commented: “Macroeconomic signals remain mixed. Tariffs, delayed decision cycles, and geopolitical uncertainty—especially in Europe—are weighing on parts of the stack. Bottom line: AI is the growth engine. IaaS is leading. SaaS is scaling. And managed services is adapting.”
About the ISG Index™
The ISG Index™ is recognized as the authoritative source for marketplace intelligence on the global technology and business services industry. For 92 consecutive quarters, it has detailed the latest industry data and trends for financial analysts, enterprise buyers, software and service providers, law firms, universities and the media.
The 3Q25 Global ISG Index results were presented during a webcast on October 9. To view a replay of the webcast and download presentation slides, visit this webpage.
About ISG
ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251014185170/en/
Contacts
Press Contacts:
Philipp Jaensch, ISG
+49 151 730 365 76
philipp.jaensch@isg-one.com
Will Thoretz, ISG
+1 203 517 3100
will.thoretz@isg-one.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom